Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing of Dabrafenib and Trametinib in BRAF-mutant Melanoma
NCT02314143Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in melanoma (3 arms), sponsored by GSK. Primary endpoints: Percentage Change from Baseline in Extracellular Signal-regulated Kinase (ERK) Phosphorylation (p-ERK) H Score at 2 weeks and Percentage Change in p-ERK H Score From Week 8 to Week 10. Started Nov 2013; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02314143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314143.